Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$421.31 USD

421.31
195,131

-2.65 (-0.63%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $421.05 -0.26 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings

Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.

Shaun Pruitt headshot

Top Stocks to Buy for Growth as Earnings Approach

Investors will want to pay attention to several top-rated Zacks stocks that are set to report their quarterly results on Monday, July 22.

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Here is how Adverum Biotechnologies (ADVM) and Medpace (MEDP) have performed compared to their sector so far this year.

Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SGRY vs. MEDP: Which Stock Is the Better Value Option?

SGRY vs. MEDP: Which Stock Is the Better Value Option?

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

Smart Beta ETF report for JSMD

Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know

The latest trading day saw Medpace (MEDP) settling at $443, representing a +1.84% change from its previous close.

Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?

Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.

Thermo Fisher (TMO) Inks New Partnership for myeloMATCH Trial

Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.

Medpace (MEDP) Upgraded to Strong Buy: Here's Why

Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Hyperfine (HYPR) Inks New Partnerships to Expand in Europe

Hyperfine (HYPR) announces that it has signed agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets for its Swoop, a portable MRI system.

STERIS (STE) AST Business Expands, New Offerings Aid Growth

STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.

Thermo Fisher (TMO) to Open New NanoPort Facility in Taiwan

Thermo Fisher (TMO) announces the opening of NanoPort, the company???s first electron microscopy demo center in Taiwan, strategically located in the region???s semiconductor manufacturing hub.

Thermo Fisher (TMO) Strategic Buyouts Aid Amid Macro Issues

Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.

Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

QIAGEN (QGEN) Expands in NGS and FIGG With New Partnership

QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.

Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy

Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.

Here's Why Holding Align Technology (ALGN) Stock Could Pay Off

Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine

Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva???s single-dose Chikungunya vaccine, IXCHIQ. The company is set to launch IXCHIQ in Europe in late 2024.

Should You Hold STERIS (STE) Stock Now? Here's What to Consider

STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.

Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues

Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.

Charles River (CRL) Could be an Apt Pick Right Now: Here's Why

Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.